MedTrace Logo

Study for Treatment of Cancer in Children With Ataxia-telangiectasia

NCT00187057 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2015-08-27

No results posted yet for this study

Summary

This is a pilot/feasibility study designed to investigate the feasibility of treating children with Ataxia-Telangiectasia (A-T) and cancer with regimens nearly as intense as non-A-T patients with cancer would receive.

Conditions

  • Ataxia-Telangiectasia

Interventions

DRUG

vinblastine, vincristine, prednisone, daunorubicin

See Detailed Description section for details of treatment interventions.

DRUG

doxorubicin, methotrexate, cyclophosphamide, L-asparaginase

See Detailed Description section for details of treatment interventions.

DRUG

etoposide, cytarabine, mercaptopurine

See Detailed Description section for details of treatment interventions.

DRUG

dexamethasone, procarbazine

See Detailed Description section for details of treatment interventions.

PROCEDURE

chemotherapy, intrathecal chemotherapy, steroid therapy

See Detailed Description section for details of treatment interventions.

Sponsors & Collaborators

Principal Investigators

  • John T. Sandlund, MD · St. Jude Children's Research Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2006-08-31
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00187057 on ClinicalTrials.gov